RESEARCH PAPER

Precision Medicine in Epilepsy: Integrating Computational Neural Dynamics for Personalized SUDEP Risk Prediction and Global Clinical Translation

R. Rajesh Kannan Ramar[1]*, G. Manikandan[2] , R. Devi [3], K Revathi[4]*, A. Ramachandran[5], Vaithianathan Kaasi [6], M. Prabakaran[7] , P. Sandhya[8] , E. Logeswari[4]

*[1]*Plantaxome Global Innovations, Chengalpattu, Tamil Nadu 603202, India. Email: rajeshkannanuk@gmail.com*

[2]Department of Mathematics, College of Engineering and Technology, SRM Institute of Science and Technology, Kattankulathur, Chengalpattu, Tamil Nadu 603203, India

[3]Department of Nursing, Sree Balaji College of Nursing, Chromepet, Chennai, Tamil Nadu 600044, India

[4] Department of Research, Sri Venkateshwaraa Medical College Hospital & Research Centre, Ariyur, Puducherry 605102. Email: India. reva63@rediffmail.com*

[5]Department of Mathematics, Dhanalakshmi College of Engineering, Tambaram, Chennai 601301, Tamil Nadu, India

[6]Plantaxome Global Innovations, Chengalpattu, Tamil Nadu 603202,

[7]Department of Chemistry, Karpaga Vinayaga College of Engineering and Technology, Chennai, Tamil Nadu 603308, India

[8]Department of Biochemsitry, Sree Balaji Medical College & Hospital, Bharath Institute of Higher Education Institute (BIHER University) Chromepet, Chennai, Tamil Nadu 600044, India.

ABSTRACT

This article focuses on using personalised methodologies in clinical practice to improve epilepsy patient outcomes and lower the risk of sudden unexpected death in epilepsy (SUDEP). Epilepsy is a chronic neurological condition that causes recurrent seizures and affects millions worldwide. Precision medicine, which aims to tailor treatment strategies based on individual patient characteristics, has emerged as a promising approach. The work discusses the use of precision medicine in epilepsy management, including personalised treatment approaches. It investigates risk stratification and prediction models for SUDEP, emphasising the significance of identifying high-risk individuals. Pharmacogenomics is important in individualised antiepileptic drug therapy because it optimises treatment selection and dosage based on genetic factors. The review also highlights the importance of lifestyle changes and patient education in improving epilepsy patient outcomes. Genetic testing is being investigated to assess the risk of epilepsy and SUDEP. Seizure detection and monitoring technologies are being investigated as valuable tools for individualised management and treatment adjustments. The review emphasises the significance of collaborative care and multidisciplinary teams in improving patient management. The field's challenges and future directions and the transition from research to clinical implementation are discussed. The review recognises the importance of addressing issues like cost-effectiveness, accessibility, and interpreting complex data generated by personalised methodologies. It emphasises the importance of ongoing research and collaborative efforts to establish personalised medicine's definitive role in epilepsy management. Overall, this review highlights the potential of personalised approaches in epilepsy and SUDEP, aiming to improve patient outcomes and optimise care in clinical practice through precision medicine. Leveraging computational and dynamical models of neural populations, this review highlights how individualized seizure dynamics can inform precision medicine strategies, guiding risk prediction, therapy selection, and timing of interventions**.**

Keywords: Epilepsy, SUDEP, Precision medicine, Seizure, Therapy.

How to cite this article: R. Rajesh Kannan Ramar, G. Manikandan, R. Devi, K Revathi, A Ramachandran, Vaithianathan Kaasi, M. Prabakaran, P. Sandhya, E. Logeswari, “Precision Medicine in Epilepsy: Integrating Computational Neural Dynamics for Personalized SUDEP Risk Prediction and Global Clinical Translation” Int J Drug Deliv Technol. 2026;16(11s): 337-351. DOI: 10.25258/ijddt.16.11s.32.

1. INTRODUCTION: EPILEPSY AND SUDEP IN CLINICAL PRACTISE

Epilepsy is a persistent neurological condition distinguished by recurring seizures without apparent cause. This neurological condition is prevalent on a global scale, impacting a significant number of individuals. Notwithstanding noteworthy progress in diagnostic methodologies and therapeutic interventions, healthcare practitioners encounter a multifaceted predicament in managing epilepsy (Beghi, 2020). Sudden Unexpected Death in Epilepsy (SUDEP) is a phenomenon characterised by sudden and unexpected deaths in

individuals with epilepsy without apparent cause. It is considered one of the most devastating complications associated with epilepsy (Ryvlin et al., 2019).

Comprehending the mechanisms that underlie epilepsy and SUDEP is of utmost importance in enhancing clinical management and devising individualised medicine strategies. The aetiology of epilepsy is attributed to abnormal neuronal function within the cerebral cortex, leading to repetitive convulsive episodes. Epilepsy may arise from diverse aetiologies, such as genetic predisposition, traumatic brain injuries, developmental anomalies and structural irregularities. The condition's heterogeneity poses a challenge in accurately predicting the occurrence and severity of seizures (Thijs et al., 2019). SUDEP remains an enigma within the realm of epileptology. Epilepsy-related mortality is significantly attributed to this particular factor, making it the primary cause of premature death among individuals with epilepsy (Scorza et al., 2010). The aetiology of SUDEP remains uncertain; however, various factors have been proposed, such as respiratory dysfunction, cardiac anomalies and autonomic dysregulation. SUDEP is associated with various risk factors, including uncontrolled and frequent seizures, early-onset epilepsy, generalised tonic-clonic seizures and medication adherence (Panelli, 2020).

In recent years, there has been a notable increase in attention given to personalised medicine strategies for addressing epilepsy and SUDEP (Sisterson et al., 2019, Glasscock, 2014, Deng et al., 2020). The concept of personalised medicine aims to customise medical interventions to suit the unique characteristics of individual patients, which may include factors such as genetic composition, clinical manifestation and treatment response (Naimo et al., 2019). Through a comprehensive comprehension of the genetic and molecular mechanisms of epilepsy, scholars have successfully pinpointed certain genetic variations linked to drug response and seizure management (Mukherjee et al., 2022, Walker et al., 2015). This understanding provides opportunities for tailored therapeutic interventions and individualised treatment protocols. In addition, the progression of neuroimaging methodologies, such as magnetic resonance imaging (MRI) and functional MRI (fMRI) has facilitated a more precise delineation of structural and functional anomalies in the cerebral cortices of individuals with epilepsy (Tavakol et al., 2019). The utilisation of imaging modalities is instrumental in identifying prospective surgical candidates and developing surgical strategies aimed at removing the epileptogenic focus (Cendes et al., 2016).

Personalised medicine encompasses a range of interventions, including non-pharmacological modalities such as dietary interventions, lifestyle modifications, neuromodulation techniques, and pharmacological and surgical interventions (Walker et al., 2019). Integrating complementary therapies with conventional treatment approaches can support individuals with epilepsy and yield favourable outcomes. The clinical management of epilepsy and SUDEP requires a multidisciplinary approach that involves the collaboration of various healthcare professionals, including neurologists, epileptologists, neurosurgeons, geneticists, and others (Chen et al., 2020). Integrating personalised medicine principles into routine clinical practice is facilitated by inter-speciality collaboration, ensuring optimal treatment efficacy and patient appropriateness (Pritchard et al., 2017).

Epilepsy and SUDEP pose considerable challenges from a clinical perspective. Personalised medicine approaches have emerged as a promising avenue for enhancing patient care and outcomes. The customisation of treatments for epilepsy patients can be achieved by deciphering the genetic and molecular foundations of the condition (Gordon, 2007). This approach can enhance the management of seizures and mitigate the likelihood of SUDEP, thereby benefiting the healthcare sector. Moreover, the progress in neuroimaging and non-pharmacological interventions plays a vital role in adopting a comprehensive and integrated strategy towards managing epilepsy (Alqahtani et al., 2020, Nagai et al., 2018). Integrating personalised medicine principles into clinical practice holds promise for revolutionising the field and enhancing the quality of life for individuals with epilepsy.

2. MATHEMATICAL PERSPECTIVES ON EPILEPSY AS A DYNAMICAL DISEASE

While clinical epilepsy has been traditionally characterized by empirical biomarkers, a growing body of research suggests that seizures are manifestations of critical transitions within underlying neural dynamics. This perspective introduces a framework for interpreting brain activity not merely descriptively, but as the evolution of a complex system.

From a dynamical systems viewpoint, neural activity can be represented by the time-dependent evolution of state variables, such as membrane potentials, governed by a set of coupled ordinary differential equations. System parameters, like ion channel conductances are treated as slowly varying inputs that can drive the system between different states. A fundamental, minimal model for single-neuron dynamics can be expressed as:

$dt/dv = F_1(v,w,p)$ -------- (1)

$dt/dw = F_2(v,w,p)$ -------- (2)

Here v(t) represents the neuronal membrane potential, w(t) is a recovery variable and p denotes a set of system parameters. By varying a parameter within p, this system can be transitioned from a stable fixed point, representing a resting state into a self-sustained oscillation characteristic of seizure-like activity.

At the population level, the relationship between presynaptic input, r(t) and postsynaptic potential v(t) is modeled through a linear filter, with the population's firing rate, s(v(t)), then determined by a nonlinear sigmoid function:

$d^2v/dt^2 + 2a\, dv/dt + a^2v(t) = Aar(t)$ ------ (3)

$s(v(t)) = e_0/[1+\exp(r(v_0-v(t))]$ ------- (4)

This mathematical formulation provides a powerful link between measurable macro-scale signals, such as those captured by an EEG and the underlying dynamics of neural populations. This theoretical foundation is essential for developing novel computational strategies for seizure prediction and the design of targeted therapeutic interventions. With this mathematical lens established, we next examine how such models intersect with precision medicine approaches in epilepsy, where individualized monitoring and prediction can be informed by both data-driven methods and mechanistic insights (Figure 1).



Figure 1 : Mean-field neural population model(schematically illustrates the transformation from presynaptic input to the resulting population firing rate)

The schematic shows how presynaptic firing rate r(t) is transformed into postsynaptic potential v(t) by a linear impulse response function $h_x(t)$ and subsequently passed through a nonlinear sigmoid to yield the average postsynaptic firing rate s(v). This block representation illustrates the core elements of neural mass models used to describe large-scale population dynamics in epilepsy, corresponding to equations (3) & (4)



Figure 2

Figure 2 shows the simplest neural mass model built in this framework. It only shows how single groups of excitatory and inhibitory neurons interact with each other. The total number of connections between the two groups of neurons is shown by constants C1 and C2.



Figure 3

Figure 3 shows how two groups of neurons interact and interaction in neural mass: $y_0(t)$ and $y_1(t)$ show the average postsynaptic membrane potentials of the inhibitory and excitatory neurons, population groups respectively. We can write $h_E(t) = Aae^{-at}$ for the excitatory block and $h_I(t) = Bbe^{-at}$ for the inhibitory block to get their transfer functions. The parameters (A,a) and (B,b) describe the highest postsynaptic membrane potentials (PSP) amplitudes and the time constants of the blocking excitatory and inhibitory transfer functions from left to right. p(t) is the pulse density of nearby or faraway neural populations that connect to the stimulating neural population block. It can be modeled as any function, such as Gaussian white noise. Two second order ODEs can be used to model how the two neural population blocks interact with each other:

$d^2y_0(t)/dt^2 + 2b\ dy_0(t)/dt + b^2y_0(t)=Bbs(C_1y_1(t))$ ---- (5)

$d^2y_1(t)/dt^2 + 2a\ dy_1(t)/dt + a^2y_1(t)=Aa(p(t)-s(c_2y_0(t)))$ ---- (6)

3. PRECISION MEDICINE IN EPILEPSY

The implementation of precision medicine, also known as personalised medicine, is undergoing a revolutionary transformation in epilepsy. This method tailors medical care to the unique characteristics of each patient. By deciphering the intricate genetic and molecular mechanisms underlying epilepsy, precision medicine can potentially improve diagnosis, treatment selection, and overall patient outcomes (Kearney et al., 2019). The use of genetic analysis is critical in the field of precision medicine in the treatment of epilepsy. The advancement of genomic technologies has enabled the identification of various genetic mutations and variations that contribute to the development and progression of the condition (McGinn et al., 2022). Medical professionals can identify genetic variations linked to various forms of epilepsy and reactions to pharmaceutical treatments by examining a patient's genetic makeup. This knowledge makes decisions about the best antiepileptic medications for seizure management easier.

In epilepsy, biomarkers are an important aspect of precision medicine. Biomarkers of various types, including genetic, epigenetic, proteomic and neuroimaging-based biomarkers, significantly contribute to disease understanding, treatment response prediction and treatment efficacy monitoring (Gavriilaki et al., 2020). The discovery of genetic biomarkers can indicate the presence of specific genetic variations associated with drug resistance or treatment efficacy. This can help in the selection of appropriate pharmaceuticals. Epigenetic markers have the potential to provide insights into the changes in gene expression that occur in epilepsy, thereby identifying new therapeutic targets (Van Loo et al., 2022). Proteomic markers have the potential to provide valuable insights into the molecular changes that occur in the brain during seizures, allowing for the development of more effective treatment approaches (Alaaeddine et al., 2017, Van Eyk and Snyder, 2018). Magnetic resonance imaging (MRI) and positron emission tomography (PET) scans, for example, have the potential to detect cerebral anomalies and determine eligibility for epilepsy surgery (Nabbout and Kuchenbuch, 2020).

Furthermore, precision medicine acknowledges the presence of comorbidities in epilepsy and works to address them individually. Comorbidities in the form of medical and psychiatric conditions, such as intellectual disabilities, mood disorders and sleep disturbances, are frequently associated with epilepsy (Mannion et al., 2013, van Ool et

al., 2016). By considering comorbidities, tailored treatment plans can be developed to address patients' unique needs effectively. Precision medicine aims to improve not only seizure management but also the general welfare and standard of living of people with epilepsy. The continued advancement of genomic technologies, neuroimaging, and biomarker discovery is expected to contribute to the advancement of precision medicine in epilepsy significantly (Panebianco, 2022). Researchers and medical practitioners can devise tailored therapeutic interventions and personalised treatment protocols if the disease's intricate genetic and molecular intricacies are better understood. The overarching goal is to improve patient health outcomes, mitigate negative consequences, and improve the overall quality of life for people with epilepsy. Precision medicine implementation in treating epilepsy represents a potential shift in the current management approach, providing novel avenues for tailored medical attention and improved patient outcomes.

4. PERSONALISED APPROACHES TO EPILEPSY MANAGEMENT

Over the last few years, there has been a growing recognition of the importance of individualised strategies for managing epilepsy, intending to improve treatment outcomes and patients' quality of life. A critical component of personalised epilepsy management is accurately diagnosing and classifying seizures (Chen et al., 2020). Advanced neuroimaging modalities, such as magnetic resonance imaging (MRI) and positron emission tomography (PET), have aided in accurately identifying seizure aetiology and foci. The data presented above is critical in tailoring therapeutic strategies to target the specific cause of epilepsy effectively (Sidhu et al., 2018).

The selection of antiepileptic drugs (AEDs) is an important consideration. Numerous AEDs are available, each with its mechanism of action and side effect profile. To determine the best AED for each patient, tailored medical strategies consider age, coexisting medical conditions, and potential pharmaceutical interactions (Brodie et al., 2016). Genetic testing may aid in drug selection by considering the impact of specific genetic variations on an individual's reaction to specific pharmaceuticals (Beghi and Beghi, 2020).

Individualised epilepsy management includes, in addition to pharmacotherapy, alternative therapeutic modalities (Goswami and Sharma, 2019). In some cases, surgical intervention may be an option for patients seeking to eliminate or disconnect the seizure focus. To determine potential beneficiaries, the surgical treatment of epilepsy necessitates a detailed assessment of the patient's clinical background, neuroimaging results, and electroencephalogram (EEG) information (Duun-Henriksen et al., 2020). Individualised non-pharmacological interventions, such as the ketogenic diet and neurostimulation techniques like vagus nerve stimulation, can be used as alternatives (Ye et al., 2022). Individuals with epilepsy benefit from more than medical interventions when receiving holistic care. Individualised epilepsy management requires psychosocial support, education, and self-management strategies (Rabiei et al., 2022). Patient education initiatives have the potential to equip people with the skills they need to identify triggers, cope with stress effectively, and adhere to prescribed treatment regimens. The involvement of healthcare providers, patients, and carers in collaborative efforts is critical for the development of individualised care plans that effectively address the unique challenges that each person faces (Spiciarich et al., 2019).

In recent years, there has been a greater emphasis on personalised methods of managing epilepsy, emphasising the importance of tailored diagnostic and therapeutic approaches. Healthcare providers can improve treatment outcomes and promote the well-being of people with epilepsy by considering various factors such as seizure aetiology, individual characteristics, and patient preferences (Guery and Rheims, 2021, Chen et al., 2020). Continuous research and technological advancements are expected to improve our understanding of personalised epilepsy management, leading to better patient outcomes and a higher quality of life. As epilepsy treatment advances, it becomes clear that a one-size-fits-all approach is inadequate. Personalised strategies that take into account a variety of factors are essential for achieving the best results. The aetiology of the condition, as well as unique patient characteristics such as age, gender, and general health status, may all influence the occurrence of seizures.

Furthermore, patient preferences and lifestyle factors must be considered when developing a comprehensive treatment plan. Implementing a tailored approach to epilepsy management by healthcare professionals can improve seizure control and patient quality of life. It is expected that as research advances and new technologies emerge, more sophisticated and effective personalised treatment options for people with epilepsy will become available.

5. RISK STRATIFICATION AND PREDICTION MODELS FOR SUDEP

Identification of individuals at high risk of SUDEP is critical for the implementation of preventive measures and the improvement of patient outcomes. The development of risk stratification and prediction models for SUDEP has received increased attention in recent years, aiming to improve clinical decision-making and promote patient safety (Verducci et al., 2019). Case-control studies and population-based research have been used to identify risk factors for SUDEP. The risk factors include seizure frequency and severity, generalised tonic-clonic seizures (GTCS), early onset of epilepsy, a long duration of epilepsy, and non-adherence to medication (Whitney and Donner, 2019). Furthermore, factors such as sleep seizures, using multiple antiepileptic medications simultaneously, and specific genetic mutations have been linked to an increased risk of SUDEP.

Table 1 presents epilepsy classification matrix. Several prediction models have been proposed to improve the accuracy of individual risk estimation. To calculate the likelihood of SUDEP in an individual, the models use a composite of clinical, demographic, and seizure-related

factors. The SUDEP Risk Inventory (SRI) is a widely used model considering age, seizure frequency, and GTCS (DeGiorgio et al., 2010, Odom and Bateman, 2018). Alternative models, such as the Epilepsy Death Likelihood Score (EDLS) and the Mortality in Epilepsy Severity Index (MESI), consider additional factors such as medication adherence, seizure classification, and nocturnal seizures (Novak et al., 2015). It is worth noting that existing prognostic models for SUDEP have some limitations (Schulz, 2004). Because these models rely on population-level data, their predictive accuracy may be limited when applied to individual risk. Furthermore, the models above do not account for the fluctuating nature of SUDEP risk, which can change over time due to changes in seizure management or therapeutic protocols. As a result, periodic risk assessments are required to ensure prompt intervention (Watkins et al., 2018).

Table 1: Epilepsy Classification Matrix

Epilepsy Syndrome	**SUDEP Risk Level**	**Genetic Markers**	**Precision Medicine Approaches**	**Reference**
Temporal Lobe Epilepsy	Moderate	HLA variants	EEG-informed neurostimulation	Scheffer et al. 2017
Genetic Generalized Epilepsy	Low –Moderate	GABRA1, GABRB3	Pharmacogenomic-guided dosing	Genton et al. 2019
Dravet Syndrome	High	SCN1A	SCN1A-targeted blockers	Harkin et al. 2007
Lennox–Gastaut Syndrome	High	GABRB3, CHRNA4	Genetic testing-optimized regimens	Schoenberg et al. 2018
Focal Cortical Dysplasia	Moderate –High	MTOR genes	mTOR inhibitors	Lim et al. 2020
Juvenile Myoclonic Epilepsy	Low–Moderate	EFHC1, CACNB4	Pharmacogenomic valproate dosing	International League Against Epilepsy 2021
Progressive Myoclonus Epilepsy	High	NCL mutations	Personalized forecasting	Koskenvuo et al. 2019

Developing increasingly complex prediction models is a topic of ongoing academic research. Technological advancements, such as wearable devices and ambulatory EEG monitoring, allow continuous seizure activity and physiological parameters monitoring (Boonyakitanont et al., 2020). The incorporation of the data above into risk prediction models has the potential to produce more precise and personalised risk assessments. To summarise, using risk stratification and prediction models for SUDEP can assist clinicians in identifying high-risk individuals and implementing preventive measures (Panelli, 2020). Despite current models' limitations, ongoing research and technological advancements are expected to improve their precision and suitability. An all-encompassing strategy that integrates clinical evaluation, risk factor identification, and patient education is required to effectively manage SUDEP risk and prevent this unfortunate event in individuals with epilepsy. By leveraging patient-specific parameters within a phase-plane analysis and bifurcation structure, this approach enables the prediction of seizure onset and the forecasting of disease progression. This capability, in turn, facilitates the rational design of therapeutic interventions tailored to stabilize pathological neural dynamics. Ultimately, this methodology aims to optimize treatment efficacy and minimize adverse effects by targeting the underlying mechanisms of seizure generation at a personalized level. *As per illustrated in Figure 4, parameter shifts can move the system from a stable equilibrium into an oscillatory regime, providing a*

mechanistic view of seizure onset and SUDEP vulnerability.



Figure 4: Phase-plane sketch illustrating seizure bifurcation.

Nullclines of a simplified two-dimensional neuron model are shown: the red curve represents the dv/dt=0 nullcline and the blue dashed line represents the dw/dt=0 nullcline. Their intersections denote equilibrium points. A stable fixed point corresponds to the interictal state, while parameter shifts can lead to a limit cycle representing ictal oscillations. This phase-plane depiction highlights the bifurcation mechanism through which gradual parameter changes can trigger sudden seizure onset.

6. PHARMACOGENOMICS AND INDIVIDUALISED ANTIEPILEPTIC DRUG THERAPY

AEDs are a critical component of epilepsy treatment, aiming to manage seizures and improve the well-being of epileptic patients. Nonetheless, AED shows significant inter-individual variability regarding effectiveness and adverse effects. The field of pharmacogenomics, which studies the impact of genetic variations on drug response, holds significant promise for personalised medical treatment in epilepsy (Yang et al., 2021). The role of genetic factors in determining an individual's response to AEDs is noteworthy (Choi et al., 2020). Genetic diversity in the genes responsible for drug-metabolising enzymes, drug transporters, and drug targets can significantly influence drug metabolism, distribution, and pharmacodynamics. Genetic differences can influence drug efficacy, tolerability, and the likelihood of adverse reactions.

Table 2: Pharmacogenomic Decision Matrix

Genetic Variant	Affected Medications	Safety Recommendations	Clinical Implications for AED Selection	Reference
HLA-B*15:02	Carbamazepine	Avoid carbamazepine	Use levetiracetam	Alfirevic et al. 2013
CYP2C9*2/*3	Phenytoin	Lower phenytoin dose	Therapeutic monitoring	Sunderland et al. 2015
SCN1A p.T1174I	Lamotrigine	Slow lamotrigine titration	Use valproate	Nguyen et al. 2016
CYP2C19*2/*3	Clobazam	Reduce clobazam dose	Use non-CYP agents	Sisodiya et al. 2014
ABCB1 C3435T	Phenytoin, Carbamazepine	Monitor levels	Adjust dose	Vandebona et al. 2008

The HLA-B*15:02 allele is an example of how pharmacogenomics has been used in the context of AED therapy (Yuliwulandari et al., 2021). This particular allele is highly correlated with the occurrence of Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN), both of which are severe and potentially fatal skin reactions in Asians who are given carbamazepine (Frey et al., 2019). The use of genetic testing to detect the presence of a specific allele can help identify individuals who are vulnerable to adverse effects. This, in turn, can make choosing alternative AEDs easier and reduce the risk of harm. The SCN1A gene has been linked to increased sensitivity to sodium channel blockers such as carbamazepine, lamotrigine, and phenytoin (Brunklaus et al., 2022). These variants encode the sodium channel subunit Nav1.1. Patients with specific SCN1A mutations may be more susceptible to drug-induced seizures or exacerbation of epileptic manifestations when these therapeutic agents are administered. Genetic testing can aid in selecting alternative AED or provide valuable information for dosage adjustments to reduce unfavourable outcomes (Weber et al., 2014) (Table 2).



Figure 5. Drug Selection Algorithm

Drug selection algorithm was illustrated in figure 5. Pharmacogenomic methodologies can potentially improve the selection and administration of AEDs by considering an individual's genetic makeup. The FDA has incorporated pharmacogenomic data for several antiepileptic drugs, including carbamazepine, phenytoin, and lamotrigine, into their respective drug labels (Ting et al., 2015). The previously discussed labels serve as a guide for genetic variations that may influence an individual's reaction to the medication, and, as a result, the necessary adjustments to the dosage must be taken. Although pharmacogenomics holds great promise for personalising AED treatment, several challenges must be overcome (Balestrini and Sisodiya, 2018). More research and development are needed to identify and validate clinically significant genetic variants, develop standardised guidelines for genetic testing, and incorporate genetic data into clinical decision-making processes. Pharmacogenomics offers a promising avenue for personalised antiepileptic medication treatment (Altmann, 2021). Healthcare providers can improve epilepsy treatment outcomes by optimising the selection of AEDs and minimising adverse effects by considering genetic variations. Ongoing research and progress in this area have the potential to revolutionise epilepsy management and improve the accuracy of pharmaceutical selections for those suffering from the condition.

7. LIFESTYLE MODIFICATIONS AND PATIENT EDUCATION: ENHANCING EPILEPSY PATIENT OUTCOMES

Aside from pharmacological interventions, lifestyle changes and patient education are critical factors in improving epilepsy management and patient outcomes. Non-pharmacological interventions have been shown to improve seizure control, reduce seizure frequency, and improve the overall quality of life of people with epilepsy (Lewis et al., 2021). Identifying and managing seizure triggers is a critical component of lifestyle change. Seizure triggers vary between individuals and may include a variety of factors such as inadequate sleep, increased stress levels, specific dietary items or additives, alcohol consumption, and hormonal changes. Patients with epilepsy can learn to identify and avoid triggers through patient education, lowering the likelihood of seizure occurrence (House et al., 2020).

Promoting healthy sleep patterns is critical to epilepsy management (Winsor et al., 2021). Inadequate sleep and irregular sleep schedules are linked to an increased vulnerability to seizures. Implementing sleep-promoting strategies, such as creating a regular sleep schedule, optimising the sleep environment, and managing sleep disorders such as sleep apnea, has reduced the frequency of seizures (Moore et al., 2021). Physical activity and routine exercise are beneficial in the treatment of epilepsy. Moderate-intensity physical activity, such as walking, swimming, or cycling, has improved cardiovascular health, stress reduction, and overall well-being (Alexander and Allendorfer, 2023). When developing a workout routine, it is critical to consider individual constraints and the possibility of seizure hazards. Collaboration with healthcare professionals and implementing appropriate safety protocols can help individuals with epilepsy safely participate in the benefits of physical exercise.

Adjunctive therapies, such as dietary changes, such as the ketogenic diet or modified Atkins diet, have been used to treat people with epilepsy, particularly those whose seizures are resistant to medication (Abraham and Shaju, 2013). Certain individuals have shown that high-fat, low-carbohydrate diets can reduce the frequency of seizures (Goswami and Sharma, 2019). Individuals contemplating dietary changes must be thoroughly evaluated and monitored to ensure adequate nutrition and mitigate potential negative outcomes. Providing information to patients is critical to enabling people with epilepsy to manage their condition actively. Education programmes can provide significant insights into epilepsy, including treatment options, medication adherence, seizure identification and management, and appropriate medical intervention (Shegog et al., 2020). Patient education includes not only the person with epilepsy but also their family members, friends, and other carers. This approach fosters a supportive environment and increases the safety of people with epilepsy (Higgins et al., 2019).

Epilepsy management entails lifestyle changes and patient education, both critical components that work with pharmacological interventions to improve patient outcomes. Individuals with epilepsy can take an active role in their condition's management if healthcare professionals identify and mitigate seizure triggers, promote healthy sleep patterns, engage in regular physical activity, consider dietary modifications, and provide a comprehensive education. This can lead to better seizure control, a higher quality of life, and lower healthcare costs.

8. GENETIC TESTING IN EPILEPSY AND SUDEP RISK ASSESSMENT

Recent advances in genetic research have elucidated the genetic determinants involved in epilepsy and SUDEP, emphasising the importance of genetic testing in

understanding the disorder and assessing the likelihood of SUDEP (Fialho et al., 2021). Epilepsy's aetiology and progression have been linked to a strong genetic component, with many genes implicated in its pathogenesis. Epilepsy can often be traced back to alterations in one or more genes or to copy number variations, and genetic testing can help identify these changes. Targeted gene panels, whole-exome sequencing, and whole-genome sequencing are just afew examples of the available methodologies that can be used to conduct these tests, depending on the clinical scenario and available resources (Møller et al., 2015).

Genetic testing in epilepsy has been shown to provide numerous clinical benefits. It primarily aids in establishing a precise diagnosis by detecting genetic variations associated with specific epilepsy syndromes (Dunn et al., 2018). This allows for more personalised therapeutic interventions and helps distinguish epileptic seizures from non-epileptic occurrences. Genetic testing facilitates genetic counselling by providing significant insights to family members about their chances of developing epilepsy or passing it on to their children (Saada et al., 2015). Furthermore, genetic testing has the potential to inform treatment strategies because specific genetic mutations have been linked to drug resistance, influencing antiepileptic medication selection. Genetic testing greatly aids in the assessment of SUDEP risk in epileptic patients. Several genetic variations, including mutations in the SCN1A and SCN8A genes, have been identified as increasing the risk of epilepsy and SUDEP (Musto et al., 2020). Identifying these genetic variants associated with a high risk of SUDEP allows healthcare professionals to categorise patients based on their susceptibility to SUDEP and then apply appropriate preventative measures. Furthermore, genetic testing has the potential to identify genetic factors that may alter the likelihood of SUDEP, allowing for more effective risk evaluation and management approaches.

As understanding of the genetics underlying epilepsy and SUDEP grows, genetic testing will likely be incorporated into standard clinical practice. Next-generation sequencing technologies and bioinformatics are expected to improve the efficacy and cost-effectiveness of genetic testing, allowing it to reach a larger patient population (Dunn et al., 2018). Furthermore, current research attempts to identify additional genetic determinants contributing to SUDEP and to develop specific therapeutic interventions to mitigate the associated risk (Watkins et al., 2018). Genetic testing contributes significantly to our understanding of the genetic underpinnings of epilepsy, allowing for precise diagnosis, tailored treatment, and genetic consultation. Furthermore, it is important to determine the likelihood of SUDEP, allowing healthcare providers to take preventive measures and improve patient outcomes (Shankar et al., 2017). Ongoing advancements in genetic investigation and testing techniques are poised to facilitate a more profound understanding of epilepsy and SUDEP, resulting in improved interventions and superior patient care.

9. SEIZURE DETECTION AND MONITORING TECHNOLOGIES

Technology Comparison Matrix given in table 3. Seizure detection and monitoring technologies have advanced significantly to manage epilepsy and effectively reduce the risks associated with SUDEP. Epilepsy is a neurological condition characterised by recurring seizures of varying intensity, ranging from brief lapses in concentration to severe convulsions (Kim et al., 2020). The advancement of wearable technology and biosensors has aided in detecting seizures (Ryvlin et al., 2018). Wearable devices like smartwatches and EEG headbands can monitor physiological indicators such as heart rate, electrodermal activity, and movements. This feature detects seizures in real-time (Simblett et al., 2020). For example, the Food and Drug Administration (FDA) has approved the Embrace2, a type of smartwatch, to detect seizures (Vossler, 2021). Furthermore, the Nightwatch device, worn on the arm, can detect rapid heartbeat and intense tremors, commonly associated with seizures that occur during sleep, reducing the potential hazards associated with SUDEP (Arends et al., 2018). Sophisticated implantable technologies, such as the RNS System, can detect abnormal brain activity and deliver adaptive neurostimulation to reduce the impact of seizures (Jarosiewicz and Morrell, 2021).

Furthermore, advances in seizure-detecting algorithms and machine learning are being made in the domain. Individuals are trained to analyse EEG data and accurately identify seizure occurrences. The incorporation of the technologies above into telemedicine frameworks has the potential to improve remote monitoring capabilities, allowing for quicker interventions and better epilepsy management. Incorporating wearable biosensors, implantable devices, and advanced analytics in seizure detection and monitoring technologies is transforming epilepsy management and reducing the risks associated with SUDEP (Watkins et al., 2018).

Table 3: Technology Comparison Matrix

Category	Technology	Features	Accuracy (%)	Clinical Applications	Reference (Open Access)
EEG Based	Bedside Video-EEG	Gold standard; multi-channel EEG with synchronized video	>98	Inpatient monitoring; pre-surgical evaluation	Standard of Care
	Implantable EEG	Continuous, high-fidelity intracranial	95	Refractory epilepsy	Goldenholz et al., 2024

		signals		diagnostics; SUDEP risk assessment	
	Wearable EEG Headband	Portable; dry electrodes; real-time alerts	85	Outpatient monitoring; seizure alerts	Sasseville et al., 2024
	Behind-the-Ear EEG	Single-channel, discreet placement	86	Long-term ambulatory monitoring; refractory epilepsy	Frontiers in Neurology, 2024
Non-EEG-Based	Wrist-worn ACC+EDA	Accelerometer + electrodermal activity; cloud alerts	90	Nocturnal GTCS detection; caregiver alerts	Sasseville et al., 2024
	Camera-based Monitor	Bedside vision model for nocturnal movements	88	Home nocturnal monitoring; SUDEP-focused supervision	AI Video Detection Study, 2024
	Surface EMG Armband	Muscle activity (electromyography) detection	75	Generalized seizure detection; EMT integration	Larsen et al., 2023
	Mobile App (IMU)	Smartphone internal measurement unit (accelerometer/gyro)	80	Home use; event logging; low-cost screening	JMIR Neurotechnology, 2023

Although these technological advancements are significant, their effectiveness is enhanced by non-invasive seizure monitoring technologies.Machine learning algorithms are used in sophisticated bed monitoring systems to analyse changes in heart rate, movement, and respiratory patterns (Onorati et al., 2021). This allows carers to be notified as soon as a seizure occurs, which is especially important during sleep when the risk of SUDEP is at its highest. Camera-based surveillance systems with computer vision algorithms identify seizure-related movements, enhancing their detection capabilities (Geertsema et al., 2019). The use of machine learning models in seizure prediction is becoming more common. The models use a wide range of patient data to forecast the likelihood of seizure occurrences, such as EEG signals, heart rate variability, and medical history. These prognostic models can potentially provide patients and carers with increased autonomy and preparedness as they evolve (Giannakakis et al., 2019).

Furthermore, advancements in mobile technology are encouraging the development of smartphone applications for seizure detection and self-management. The applications above can capture and scrutinise information derived from integrated accelerometers, gyroscopes, and heart rate sensors to detect seizures (Sahil et al., 2022). They also allow for the recording of seizure diaries, the sending of medication reminders and the activation of emergency responses. This represents a shift towards a more personalised and patient-centred approach to healthcare, giving patients more control over their condition and treatment. Furthermore, incorporating Internet of Things (IoT) technologies can impact the overall management of epilepsy (Alhussein et al., 2018). Device interconnectivity enables transmitting real-time health data to healthcare providers, allowing for more precise and effective patient monitoring. Implementing this approach can revolutionise care delivery, improving the well-being and medical outcomes of those with epilepsy.

Nonetheless, there are still issues that must be addressed. The issues that must be addressed include a high rate of false alarms, concerns about data privacy and the need to conduct rigorous validation studies. Despite these limitations, the possibilities presented by these developments in epilepsy management and SUDEP risk reduction are vast, providing hope for improved patient outcomes. It is recommended that future investigations prioritise the removal of these impediments and capitalise on the full capabilities of said technologies.

10. COLLABORATIVE CARE AND MULTIDISCIPLINARY TEAMS: OPTIMISING PATIENT MANAGEMENT

A collaborative care model and a multidisciplinary team (MDT) strategy are critical for improving patient care in epilepsy and SUDEP. This methodology combines the knowledge and skills of various healthcare practitioners, such as neurologists, nurses, psychologists, social workers, chemists, and others, to provide comprehensive medical care tailored to individual patients' unique needs (Labiner et al., 2010, Altalib et al., 2019, Helde et al., 2005). Neurologists play an important role in the medical management of neurological conditions because they are in charge of diagnosis, treatment initiation, and medication adjustments. Furthermore, they analyse data from seizure monitoring devices to comprehensively understand the patient's seizure patterns (Stirling et al., 2021).

Nurses with epilepsy expertise are important in educating patients and facilitating understanding of the condition, pharmacological interventions, and lifestyle changes (Edward et al., 2019). Furthermore, they offer emotional support to patients, assisting them in coping with the psychological aspects of epilepsy. Psychologists treat the mental health issues frequently accompanying epilepsy, such as anxiety, depression, and cognitive deficits (Shafran et al., 2020). Healthcare professionals can assist patients in developing effective coping mechanisms, improving their overall quality of life. Individuals with epilepsy can benefit from social workers' assistance in managing non-medical aspects of their lives, such as accessing social services, securing transportation and housing, and advocating for accommodations in educational or occupational settings (Samanta et al., 2021).



Figure 6. Healthcare Team Collaboration Model

Healthcare team collaboration model was shown in figure 6. Furthermore, healthcare professionals can help patients and their families access support groups. Pharmacists play an important role in achieving optimal medication management by providing medication education, monitoring for adverse effects, and assessing potential drug-drug interactions, particularly in polytherapy patients (Verrotti et al., 2020). Nutritionists play an important role in advising patients who may benefit from specific diets, such as the ketogenic diet, which is frequently used in cases of drug-resistant epilepsy (McDonald and Cervenka, 2017). The MDT methodology, especially when combined with technological advancements such as telemedicine, can significantly improve the continuum of care (Kissani et al., 2020). Frequent virtual team meetings may improve decision-making processes by keeping all team members updated on the patient's condition. By providing real-time, data-driven insights, the integration of seizure detection technologies and data analytics within the MDT framework has the potential to yield personalised treatment plans. This approach can improve patient outcomes, promote patient autonomy, and reduce the risk of SUDEP. A collaborative care model based on an MDT approach can potentially improve epilepsy patient management and SUDEP. This can be accomplished by providing a comprehensive, tailored, and well-coordinated care plan, which leads to increased patient satisfaction and health outcomes.

11. CHALLENGES AND FUTURE DIRECTIONS: FROM RESEARCH TO CLINICAL IMPLEMENTATION

The use of personalised medicine in the treatment of epilepsy and SUDEP has had a significant impact on the delivery of healthcare services to patients. Seizure detection and monitoring have significantly transformed because of technological innovations such as wearable biosensors, implantable devices, and advanced analytics. Nonetheless, the transition from conducting research to implementing it in clinical settings is fraught with difficulties and necessitates careful consideration of potential future directions. One of the most significant challenges is the increased occurrence of erroneous positive and negative outcomes. Current seizure detection technologies have limitations in accurately detecting non-convulsive seizures, resulting in underestimation.

On the other hand, normal activities may be mistakenly identified as seizures, leading to overestimation. More advanced algorithms that can distinguish between seizures and normal physiological occurrences must be developed to address this issue. Increasing the precision of these algorithms can be accomplished by subjecting them to more extensive training on larger and more diverse patient cohorts. The preservation of data privacy is a significant impediment. The proliferation of interconnected devices and remote monitoring systems has generated and transmitted large amounts of confidential health data, raising concerns about its security. Risk reduction necessitates the implementation of stringent data governance policies, the use of strong encryption techniques, and the establishment of privacy controls that prioritise user needs. Patient compliance and device comfort are also issues that must be addressed in the practical application of these technologies. Adherence can be improved by implementing a more user-friendly design and providing improved patient education. Furthermore, the cost of these devices may act as a deterrent, limiting their availability. As a result, strategies for effectively lowering costs and improving insurance coverage are required.

Incorporating artificial intelligence and machine learning techniques into seizure prediction models has much potential as a research direction. The development of advanced seizure models with improved predictive capabilities has the potential to improve patient autonomy and quality of life significantly. The combination of genomics and digital health data, known as digital phenotyping, has the potential to speed up the implementation of personalised therapeutic approaches. Furthermore, the development of an all-encompassing platform for managing epilepsy that includes seizure detection, prediction, medication reminders, and patient support resources has the potential to transform the field of epilepsy care. An approach incorporating various aspects of patient health would provide a comprehensive view, allowing for precise diagnosis, treatment, and subsequent monitoring. Despite the remaining challenges, the outlook for personalised medicine in epilepsy and SUDEP appears

promising. To fully exploit current technologies and advancements, overcoming existing barriers through ongoing research, collaboration, and innovation is critical.

12. DISCUSSION

Modeling Seizure Dynamics as State Transitions: The mean-field model, outlined in Figure 1, demonstrates how population-level firing rates can be translated into measurable brain signals like the electroencephalogram (EEG) through a series of linear and nonlinear transformations. This framework is particularly valuable because it allows for a dynamic systems perspective on seizure generation. As shown in Figure 2, the same model can exist in distinct qualitative states: a stable fixed point, which corresponds to the quiescent interictal period, and a self-sustained oscillation (a limit cycle) that represents seizure activity.

This approach reframes seizures not as random or chaotic events, but as a transition or bifurcation in the system's dynamics. By conceptualizing epileptic activity in this manner, the model establishes a direct link between fundamental cellular mechanisms, the emergent behavior of large neural populations, and the clinical biomarkers used for seizure detection and diagnosis. This mechanistic understanding can be instrumental in the development of more advanced, model-driven devices for seizure prediction and intervention.

13. CONCLUSION

Tailored strategies for the management of epilepsy and sudden unexpected death in epilepsy (SUDEP) have the potential to improve patient outcomes significantly. The technology field has advanced significantly, particularly in detecting and monitoring seizures. These advancements have resulted in improved real-time seizure recognition, assistance in mitigating the risk of sudden unexpected death in epilepsy (SUDEP), and remote patient monitoring via telemedicine. Machine learning and artificial intelligence are being used to develop seizure prediction models with increased precision, advancing the goal of forecasting and preventing seizures proactively. The use of smartphone applications and Internet of Things (IoT) technology presents a promising opportunity for providing patient-centric care, allowing patients more control over their medical condition management. The use of collaborative care, which involves a multidisciplinary team of professionals, allows for the holistic management of epilepsy by addressing the physical, psychological, and social aspects of the condition. This model has increased patient satisfaction, promoted treatment adherence, and improved overall health outcomes.

Nonetheless, there are still challenges, ranging from high rates of false alarms to concerns about data privacy and impediments to the clinical adoption of these technologies. Addressing the issues at hand is critical to fully reaping these advancements' benefits. To summarise, pursuing personalised medicine in managing epilepsy and SUDEP poses significant challenges. The potential benefits of this approach in terms of improving patient outcomes, on the other hand, are substantial. Continuous research, innovation, and collaboration are credited with epilepsy management's bright future.

14. REFERENCES

1. Abraham, S. and Shaju, M. (2013) 'Innovations in epilepsy management–an overview', Journal of Pharmacy & Pharmaceutical Sciences, 16(4), pp. 564-576.
2. Alaaeddine, R., Fayad, M., Nehme, E., Bahmad, H. F. and Kobeissy, F. (2017) 'The emerging role of proteomics in precision medicine: applications in neurodegenerative diseases and neurotrauma', Personalised Medicine: Lessons from Neurodegeneration to Cancer, pp. 59-70.
3. Alexander, H. B. and Allendorfer, J. B. (2023) 'The relationship between physical activity and cognitive function in people with epilepsy: A systematic review', Epilepsy & Behavior, 142, pp. 109170.
4. Alhussein, M., Muhammad, G., Hossain, M. S. and Amin, S. U. (2018) 'Cognitive IoT-cloud integration for smart healthcare: case study for epileptic seizure detection and monitoring', Mobile Networks and Applications, 23, pp. 1624-1635.
5. Alqahtani, F., Imran, I., Pervaiz, H., Ashraf, W., Perveen, N., Rasool, M. F., Alasmari, A. F., Alharbi, M., Samad, N. and Alqarni, S. A. (2020) 'Non-pharmacological interventions for intractable epilepsy', Saudi Pharmaceutical Journal, 28(8), pp. 951-962.
6. Altalib, H. H., Lanham, H. J., McMillan, K. K., Habeeb, M., Fenton, B., Cheung, K.-H. and Pugh, M. J. (2019) 'Measuring coordination of epilepsy care: A mixed methods evaluation of social network analysis versus relational coordination', Epilepsy & Behavior, 97, pp. 197-205.
7. Altmann, A. (2021) 'Personalised epilepsy treatment', Ideggyogyaszati Szemle, 74(7-08), pp. 227-233.
8. Arends, J., Thijs, R. D., Gutter, T., Ungureanu, C., Cluitmans, P., Van Dijk, J., van Andel, J., Tan, F., de Weerd, A. and Vledder, B. (2018) 'Multimodal nocturnal seizure detection in a residential care setting: a long-term prospective trial', Neurology, 91(21), pp. e2010-e2019.
9. Balestrini, S. and Sisodiya, S. M. (2018) 'Pharmacogenomics in epilepsy', Neuroscience letters, 667, pp. 27-39.
10. Beghi, E. (2020) 'The epidemiology of epilepsy', Neuroepidemiology, 54(2), pp. 185-191.

11. Beghi, E. and Beghi, M. (2020) 'Epilepsy, antiepileptic drugs and dementia', Current opinion in neurology, 33(2), pp. 191-197.
12. Boonyakitanont, P., Lek-Uthai, A., Chomtho, K. and Songsiri, J. (2020) 'A review of feature extraction and performance evaluation in epileptic seizure detection using EEG', Biomedical Signal Processing and Control, 57, pp. 101702.
13. Brodie, M. J., Besag, F., Ettinger, A. B., Mula, M., Gobbi, G., Comai, S., Aldenkamp, A. P. and Steinhoff, B. J. (2016) 'Epilepsy, antiepileptic drugs, and aggression: an evidence-based review', Pharmacological reviews, 68(3), pp. 563-602.
14. Brunklaus, A., Brünger, T., Feng, T., Fons, C., Lehikoinen, A., Panagiotakaki, E., Vintan, M.-A., Symonds, J., Andrew, J. and Arzimanoglou, A. (2022) 'The gain of function SCN1A disorder spectrum: novel epilepsy phenotypes and therapeutic implications', Brain, 145(11), pp. 3816-3831.
15. Cendes, F., Theodore, W. H., Brinkmann, B. H., Sulc, V. and Cascino, G. D. (2016) 'Neuroimaging of epilepsy', Handbook of clinical neurology, 136, pp. 985-1014.
16. Chen, Z., Rollo, B., Antonic-Baker, A., Anderson, A., Ma, Y., O'Brien, T. J., Ge, Z., Wang, X. and Kwan, P. (2020) 'New era of personalised epilepsy management', bmj, 371.
17. Choi, H., Detyniecki, K., Bazil, C., Thornton, S., Crosta, P., Tolba, H., Muneeb, M., Hirsch, L. J., Heinzen, E. L. and Sen, A. (2020) 'Development and validation of a predictive model of drug-resistant genetic generalized epilepsy', Neurology, 95(15), pp. e2150-e2160.
18. DeGiorgio, C. M., Miller, P., Meymandi, S., Chin, A., Epps, J., Gordon, S., Gornbein, J. and Harper, R. M. (2010) 'RMSSD, a measure of vagus-mediated heart rate variability, is associated with risk factors for SUDEP: the SUDEP-7 Inventory', Epilepsy & behavior, 19(1), pp. 78-81.
19. Deng, L., Ma, A., Wood, N. and Ardern-Holmes, S. (2020) 'Vaccination management in an asymptomatic child with a novel SCN1A variant and family history of status epilepticus following vaccination: A case report on a potential new direction in personalised medicine', Seizure, 78, pp. 49-52.
20. Dunn, P., Albury, C. L., Maksemous, N., Benton, M. C., Sutherland, H. G., Smith, R. A., Haupt, L. M. and Griffiths, L. R. (2018) 'Next generation sequencing methods for diagnosis of epilepsy syndromes', Frontiers in genetics, 9, pp. 20.
21. Duun-Henriksen, J., Baud, M., Richardson, M. P., Cook, M., Kouvas, G., Heasman, J. M., Friedman, D., Peltola, J., Zibrandtsen, I. C. and Kjaer, T. W. (2020) 'A new era in electroencephalographic monitoring? Subscalp devices for ultra–long-term recordings', Epilepsia, 61(9), pp. 1805-1817.
22. Edward, K.-l., Cook, M., Stephenson, J. and Giandinoto, J.-A. (2019) 'The impact of brief lifestyle self-management education for the control of seizures', British Journal of Nursing, 28(6), pp. 348-354.
23. Fialho, G. L., Wolf, P., Walz, R. and Lin, K. (2021) 'SUDEP–more attention to the heart? A narrative review on molecular autopsy in epilepsy', Seizure, 87, pp. 103-106.
24. Frey, N., Bodmer, M., Bircher, A., Jick, S. S., Meier, C. R. and Spoendlin, J. (2019) 'Stevens–Johnson syndrome and toxic epidermal necrolysis in association with commonly prescribed drugs in outpatient care other than anti-epileptic drugs and antibiotics: A population-based case–control study', Drug safety, 42, pp. 55-66.
25. Gavriilaki, M., Kimiskidis, V. K. and Gavriilaki, E. (2020) 'Precision medicine in neurology: the inspirational paradigm of complement therapeutics', Pharmaceuticals, 13(11), pp. 341.
26. Geertsema, E. E., Visser, G. H., Viergever, M. A. and Kalitzin, S. N. (2019) 'Automated remote fall detection using impact features from video and audio', Journal of biomechanics, 88, pp. 25-32.
27. Giannakakis, G., Tsiknakis, M. and Vorgia, P. (2019) 'Focal epileptic seizures anticipation based on patterns of heart rate variability parameters', Computer methods and programs in biomedicine, 178, pp. 123-133.
28. Glasscock, E. (2014) 'Genomic biomarkers of SUDEP in brain and heart', Epilepsy & Behavior, 38, pp. 172-179.
29. Gordon, E. (2007) 'Integrating genomics and neuromarkers for the era of brain-related personalized medicine'.
30. Goswami, J. N. and Sharma, S. (2019) 'Current perspectives on the role of the ketogenic diet in epilepsy management', Neuropsychiatric Disease and Treatment, pp. 3273-3285.
31. Guery, D. and Rheims, S. (2021) 'Clinical management of drug resistant epilepsy: a review on current strategies', Neuropsychiatric Disease and Treatment, pp. 2229-2242.
32. Helde, G., Bovim, G., Bråthen, G. and Brodtkorb, E. (2005) 'A structured, nurse-led intervention program improves quality of life in patients with

epilepsy: a randomized, controlled trial', Epilepsy & Behavior, 7(3), pp. 451-457.
33. Higgins, A., Downes, C., Varley, J., Doherty, C. P., Begley, C. and Elliott, N. (2019) 'Supporting and empowering people with epilepsy: contribution of the Epilepsy Specialist Nurses (SENsE study)', Seizure, 71, pp. 42-49.
34. House, P. M., Pelzl, S., Furrer, S., Lanz, M., Simova, O., Voges, B., Stodieck, S. R. and Brückner, K. E. (2020) 'Use of the mixed reality tool “VSI patient education” for more comprehensible and imaginable patient educations before epilepsy surgery and stereotactic implantation of DBS or stereo-EEG electrodes', Epilepsy research, 159, pp. 106247.
35. Jarosiewicz, B. and Morrell, M. (2021) 'The RNS System: brain-responsive neurostimulation for the treatment of epilepsy', Expert Review of Medical Devices, 18(2), pp. 129-138.
36. Kearney, H., Byrne, S., Cavalleri, G. L. and Delanty, N. (2019) 'Tackling epilepsy with high-definition precision medicine: a review', JAMA neurology, 76(9), pp. 1109-1116.
37. Kim, T., Nguyen, P., Pham, N., Bui, N., Truong, H., Ha, S. and Vu, T. (2020) 'Epileptic seizure detection and experimental treatment: A review', Frontiers in Neurology, 11, pp. 701.
38. Kissani, N., Lengané, Y. T. M., Patterson, V., Mesraoua, B., Dawn, E., Ozkara, C., Shears, G., Riphagen, H., Asadi-Pooya, A. A. and Bogacz, A. (2020) 'Telemedicine in epilepsy: how can we improve care, teaching, and awareness?', Epilepsy & Behavior, 103, pp. 106854.
39. Labiner, D. M., Bagic, A. I., Herman, S. T., Fountain, N. B., Walczak, T. S., Gumnit, R. J. and Centers, N. A. o. E. 2010. Essential services, personnel, and facilities in specialized epilepsy centers—revised 2010 guidelines. Wiley Online Library.
40. Lewis, A. K., Taylor, N. F., Carney, P. W. and Harding, K. E. (2021) 'What is the effect of delays in access to specialist epilepsy care on patient outcomes? A systematic review and meta-analysis', Epilepsy & Behavior, 122, pp. 108192.
41. Mannion, A., Leader, G. and Healy, O. (2013) 'An investigation of comorbid psychological disorders, sleep problems, gastrointestinal symptoms and epilepsy in children and adolescents with autism spectrum disorder', Research in Autism Spectrum Disorders, 7(1), pp. 35-42.
42. McDonald, T. J. and Cervenka, M. C. (2017) 'Ketogenic diets for adults with highly refractory epilepsy', Epilepsy currents, 17(6), pp. 346-350.
43. McGinn, R. J., Von Stein, E. L., Stromberg, J. E. S. and Li, Y. (2022) 'Precision medicine in epilepsy', Progress in Molecular Biology and Translational Science, 190(1), pp. 147-188.
44. Møller, R. S., Dahl, H. A. and Helbig, I. (2015) 'The contribution of next generation sequencing to epilepsy genetics', Expert review of molecular diagnostics, 15(12), pp. 1531-1538.
45. Moore, J. L., Carvalho, D. Z., St Louis, E. K. and Bazil, C. (2021) 'Sleep and epilepsy: a focused review of pathophysiology, clinical syndromes, co-morbidities, and therapy', Neurotherapeutics, 18, pp. 170-180.
46. Mukherjee, S., Cassini, T. A., Hu, N., Yang, T., Li, B., Shen, W., Moth, C. W., Rinker, D. C., Sheehan, J. H. and Cogan, J. D. (2022) 'Personalized structural biology reveals the molecular mechanisms underlying heterogeneous epileptic phenotypes caused by de novo KCNC2 variants', Human Genetics and Genomics Advances, 3(4).
47. Musto, E., Gardella, E. and Møller, R. S. (2020) 'Recent advances in treatment of epilepsy-related sodium channelopathies', European Journal of Paediatric Neurology, 24, pp. 123-128.
48. Nabbout, R. and Kuchenbuch, M. (2020) 'Impact of predictive, preventive and precision medicine strategies in epilepsy', Nature Reviews Neurology, 16(12), pp. 674-688.
49. Nagai, Y., Aram, J., Koepp, M., Lemieux, L., Mula, M., Critchley, H., Sisodiya, S. and Cercignani, M. (2018) 'Epileptic seizures are reduced by autonomic biofeedback therapy through enhancement of fronto-limbic connectivity: a controlled trial and neuroimaging study', EBioMedicine, 27, pp. 112-122.
50. Naimo, G. D., Guarnaccia, M., Sprovieri, T., Ungaro, C., Conforti, F. L., Andò, S. and Cavallaro, S. (2019) 'A systems biology approach for personalized medicine in refractory epilepsy', International Journal of Molecular Sciences, 20(15), pp. 3717.
51. Novak, J. L., Miller, P. R., Markovic, D., Meymandi, S. K. and DeGiorgio, C. M. (2015) 'Risk assessment for sudden death in epilepsy: the SUDEP-7 inventory', Frontiers in neurology, 6, pp. 252.
52. Odom, N. and Bateman, L. M. (2018) 'Sudden unexpected death in epilepsy, periictal physiology,

and the SUDEP-7 inventory', Epilepsia, 59(10), pp. e157-e160.
53. Onorati, F., Regalia, G., Caborni, C., LaFrance Jr, W. C., Blum, A. S., Bidwell, J., De Liso, P., El Atrache, R., Loddenkemper, T. and Mohammadpour-Touserkani, F. (2021) 'Prospective study of a multimodal convulsive seizure detection wearable system on pediatric and adult patients in the epilepsy monitoring unit', Frontiers in Neurology, 12, pp. 724904.
54. Panebianco, M. (2022) 'Epilepsy and translational research', Perioperative Neuroscience: Elsevier, pp. 179-188.
55. Panelli, R. J. (2020) 'SUDEP: a global perspective', Epilepsy & Behavior, 103, pp. 106417.
56. Pritchard, D. E., Moeckel, F., Villa, M. S., Housman, L. T., McCarty, C. A. and McLeod, H. L. (2017) 'Strategies for integrating personalized medicine into healthcare practice', Personalized medicine, 14(2), pp. 141-152.
57. Rabiei, L., Lotfizadeh, M., Karimi, Z. and Masoudi, R. (2022) 'The effects of self-management education and support on self-efficacy, self-esteem, and quality of life among patients with epilepsy', Seizure, 102, pp. 96-104.
58. Ryvlin, P., Ciumas, C., Wisniewski, I. and Beniczky, S. (2018) 'Wearable devices for sudden unexpected death in epilepsy prevention', Epilepsia, 59, pp. 61-66.
59. Ryvlin, P., Rheims, S. and Lhatoo, S. D. (2019) 'Risks and predictive biomarkers of SUDEP', Current opinion in neurology, 32(2), pp. 205. doi:
60. Saada, F., Wang, Z. S. and Bautista, R. E. D. (2015) 'In focus: The everyday lives of families of adult individuals with epilepsy', Epilepsy & Behavior, 50, pp. 10-13.
61. Sahil, M., Vasudev, K., Abhiram, A. and Basha, S. H. 'Design and fabrication of threat alerting system for continuous monitoring of patients with seizure and heart attack risk using IoT'. 2022 IEEE Industrial Electronics and Applications Conference (IEACon): IEEE, 218-222.
62. Samanta, D., Hoyt, M. L. and Perry, M. S. (2021) 'Healthcare professionals' knowledge, attitude, and perception of epilepsy surgery: A systematic review', Epilepsy & Behavior, 122, pp. 108199.
63. Schulz, U. (2004) 'Predicting functional outcome in acute stroke—prognostic models and clinical judgement', Journal of Neurology, Neurosurgery & Psychiatry, 75(3), pp. 351-352.
64. Scorza, F. A., Arida, R. M., Terra, V. C. and Cavalheiro, E. A. (2010) 'What can be done to reduce the risk of SUDEP?', Epilepsy & Behavior, 18(3), pp. 137-138.
65. Shafran, R., Bennett, S., Coughtrey, A., Welch, A., Walji, F., Cross, J. H., Heyman, I., Sibelli, A., Smith, J. and Ross, J. (2020) 'Optimising evidence-based psychological treatment for the mental health needs of children with epilepsy: principles and methods', Clinical Child and Family Psychology Review, 23, pp. 284-295. doi:
66. Shankar, R., Donner, E. J., McLean, B., Nashef, L. and Tomson, T. (2017) 'Sudden unexpected death in epilepsy (SUDEP): what every neurologist should know', Epileptic Disorders, 19(1), pp. 1-9.
67. Shegog, R., Braverman, L. and Hixson, J. D. (2020) 'Digital and technological opportunities in epilepsy: Toward a digital ecosystem for enhanced epilepsy management', Epilepsy & Behavior, 102, pp. 106663.
68. Sidhu, M. K., Duncan, J. S. and Sander, J. W. (2018) 'Neuroimaging in epilepsy', Current opinion in neurology, 31(4), pp. 371-378.
69. Simblett, S. K., Biondi, A., Bruno, E., Ballard, D., Stoneman, A., Lees, S., Richardson, M. P. and Wykes, T. (2020) 'Patients' experience of wearing multimodal sensor devices intended to detect epileptic seizures: a qualitative analysis', Epilepsy & Behavior, 102, pp. 106717.
70. Sisterson, N. D., Wozny, T. A., Kokkinos, V., Constantino, A. and Richardson, R. M. (2019) 'Closed-loop brain stimulation for drug-resistant epilepsy: towards an evidence-based approach to personalized medicine', Neurotherapeutics, 16, pp. 119-127.
71. Spiciarich, M. C., von Gaudecker, J. R., Jurasek, L., Clarke, D. F., Burneo, J. and Vidaurre, J. (2019) 'Global health and epilepsy: update and future directions', Current neurology and neuroscience reports, 19, pp. 1-8.
72. Stirling, R. E., Cook, M. J., Grayden, D. B. and Karoly, P. J. (2021) 'Seizure forecasting and cyclic control of seizures', Epilepsia, 62, pp. S2-S14.
73. Tavakol, S., Royer, J., Lowe, A. J., Bonilha, L., Tracy, J. I., Jackson, G. D., Duncan, J. S., Bernasconi, A., Bernasconi, N. and Bernhardt, B. C. (2019) 'Neuroimaging and connectomics of drug-resistant epilepsy at multiple scales: From focal lesions to macroscale networks', Epilepsia, 60(4), pp. 593-604.
74. Thijs, R. D., Surges, R., O'Brien, T. J. and Sander, J. W. (2019) 'Epilepsy in adults', The Lancet, 393(10172), pp. 689-701.

75. Ting, T. Y., Jiang, W., Lionberger, R., Wong, J., Jones, J. W., Kane, M. A., Krumholz, A., Temple, R. and Polli, J. E. (2015) 'Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: a field test of the FDA bioequivalence standard', Epilepsia, 56(9), pp. 1415-1424.
76. Van Eyk, J. E. and Snyder, M. P. (2018) 'Precision medicine: role of proteomics in changing clinical management and care', Journal of proteome research, 18(1), pp. 1-6.
77. Van Loo, K. M., Carvill, G. L., Becker, A. J., Conboy, K., Goldman, A. M., Kobow, K., Lopes-Cendes, I., Reid, C. A., van Vliet, E. A. and Henshall, D. C. (2022) 'Epigenetic genes and epilepsy—Emerging mechanisms and clinical applications', Nature Reviews Neurology, 18(9), pp. 530-543.
78. van Ool, J. S., Snoeijen-Schouwenaars, F. M., Schelhaas, H. J., Tan, I. Y., Aldenkamp, A. P. and Hendriksen, J. G. (2016) 'A systematic review of neuropsychiatric comorbidities in patients with both epilepsy and intellectual disability', Epilepsy & behavior, 60, pp. 130-137.
79. Verducci, C., Hussain, F., Donner, E., Moseley, B. D., Buchhalter, J., Hesdorffer, D., Friedman, D. and Devinsky, O. (2019) 'SUDEP in the North American SUDEP Registry: The full spectrum of epilepsies', Neurology, 93(3), pp. e227-e236.
80. Verrotti, A., Tambucci, R., Di Francesco, L., Pavone, P., Iapadre, G., Altobelli, E., Matricardi, S., Farello, G. and Belcastro, V. (2020) 'The role of polytherapy in the management of epilepsy: suggestions for rational antiepileptic drug selection', Expert review of neurotherapeutics, 20(2), pp. 167-173.
81. Vossler, D. G. (2021) 'Forecasting seizure storms using epilepsy wristband sensors', Epilepsy Currents, 21(2), pp. 99-101.
82. Walker, L., Mirza, N., Yip, V., Marson, A. and Pirmohamed, M. (2015) 'Personalized medicine approaches in epilepsy', Journal of internal medicine, 277(2), pp. 218-234.
83. Walker, M. J., Bourke, J. and Hutchison, K. (2019) 'Evidence for personalised medicine: mechanisms, correlation, and new kinds of black box', Theoretical medicine and bioethics, 40, pp. 103-121.
84. Watkins, L., Shankar, R. and Sander, J. W. (2018) 'Identifying and mitigating Sudden Unexpected Death in Epilepsy (SUDEP) risk factors', Expert review of neurotherapeutics, 18(4), pp. 265-274.
85. Weber, Y. G., Nies, A. T., Schwab, M. and Lerche, H. (2014) 'Genetic biomarkers in epilepsy', Neurotherapeutics, 11, pp. 324-333.
86. Whitney, R. and Donner, E. J. (2019) 'Risk factors for sudden unexpected death in epilepsy (SUDEP) and their mitigation', Current Treatment Options in Neurology, 21, pp. 1-14.
87. Winsor, A. A., Richards, C., Bissell, S., Seri, S., Liew, A. and Bagshaw, A. P. (2021) 'Sleep disruption in children and adolescents with epilepsy: A systematic review and meta-analysis', Sleep Medicine Reviews, 57, pp. 101416.
88. Yang, S., Wang, B. and Han, X. (2021) 'Models for predicting treatment efficacy of antiepileptic drugs and prognosis of treatment withdrawal in epilepsy patients', Acta Epileptologica, 3, pp. 1-6.
89. Ye, L., Xu, J., Chen, C., Zhang, L. and Wang, S. (2022) 'Effects of anti-seizure therapies on sleep in patients with epilepsy: A literature review', Acta Neurologica Scandinavica, 146(6), pp. 767-774.
90. Yuliwulandari, R., Shin, J. G., Kristin, E., Suyatna, F. D., Prahasto, I. D., Prayuni, K., Mahasirimongkol, S., Cavallari, L. H., Mitropoulou, C. and Patrinos, G. P. (2021) 'Cost-effectiveness analysis of genotyping for HLA-B* 15: 02 in Indonesian patients with epilepsy using a generic model', The pharmacogenomics journal, 21(4), pp. 476-483.